Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM6D30Q)

Drug Name
TAK-341 Drug Info
Indication
Disease Entry ICD 11 Status REF
Multiple system atrophy 8D87.0 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM6D30Q

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Synuclein alpha (SNCA) TT08OSU SYUA_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Synuclein alpha (SNCA) DTT SNCA 5.221 5.594 5.585 5.781
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Multiple system atrophy
ICD Disease Classification 8D87.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Synuclein alpha (SNCA) DTT SNCA 1.04E-01 -0.26 -0.33
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05526391) A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy. U.S.National Institutes of Health.
2 Preclinical development of a high affinity alpha-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular alpha-synuclein and attenuate alpha-synuclein spreading in vivo. Neurobiol Dis. 2019 Dec;132:104582.